All Updates

All Updates

icon
Filter
Funding
Partnerships
Erasca signs USD 20 million deal with Novartis; raises USD 100 million in underwritten public offering
AI Drug Discovery
Dec 9, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Dec 9, 2022

Erasca signs USD 20 million deal with Novartis; raises USD 100 million in underwritten public offering

Funding
Partnerships

  • California-based AI biotechnology company Erasca signed an agreement with big pharma Novartis to license the latter’s melanoma drug naporafenib for mid-stage development. 

  • As per the agreement. Novartis will be paid USD 20 million upfront cash together with USD 80 million in shares at a rate of USD 6.50 per share. In addition to that, Novartis is eligible for USD 80 million upon achieving regulatory milestones, and another USD 200 million upon achieving sales milestones.

  • Simultaneously, Erasca raised USD 100 million in an underwritten equity offering of 15.4 million common shares at a rate of USD 6.50 per share. The offering is expected to close on or about December 13, 2022, subject to the fulfillment of certain closing conditions.

  • The proceeds from the offering will be directed toward the company’s R&D efforts, and advance its development programs. It will also be used for working capital and general purposes.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.